ReviewHerpes simplex virus resistance to antiviral drugs
Introduction
Herpes simplex virus (HSV) infections are common and may be responsible for serious complications among immunocompromised patients. The treatment of choice is acyclovir (ACV) which is a nucleoside analogue of guanosine that has to be phosphorylated three times. The first phosphorylation is completed by the viral encoded thymidine kinase (TK) protein which allows ACV to become active only in virus infected cells. The second and third phosphorylations are achieved by cellular thymidylate kinases. ACV triphosphate acts by competitive inhibition of viral DNA polymerase and it is a DNA chain terminator (Elion, 1993).
This widespread use of ACV has lead to the emergence of HSV strains resistant to ACV. Resistant strains were soon reported and the first cases of clinical resistant strains were published in 1982 (Sibrack et al., 1982, Crumpacker et al., 1982, Burns et al., 1982). Large surveys were conducted and revealed the low incidence of ACV-resistant strains among immunocompetent patients, from 0 to 0.6% (Englund et al., 1990, Nugier et al., 1992, Christophers et al., 1998). Conversely ACV-resistant strains were most often recovered from immunocompromised patients with a whole frequency ranging from 3 to 6%, that reaches 14% among bone marrow transplant recipients (Englund et al., 1990, Nugier et al., 1992, Christophers et al., 1998).
This review deals with clinical and epidemiological features associated with the emergence of ACV-resistant HSV, mechanisms of resistance, management of ACV-resistant HSV infections and presents an analysis of recently published data on mutations associated with resistance.
Section snippets
Epidemiology
Among immunocompetent patients, resistance to ACV is rare. Several reports have described a prevalence below 1% in this population (Nugier et al., 1992, Christophers et al., 1998). In our hospital laboratory, all HSV isolated were tested for their sensitivity to ACV; ACV-resistant strains have never been detected among immunocompetent patients during more than 10 years of surveillance (more than 500 isolates tested) (unpublished results).
According to the literature, most ACV-resistant HSV
Mechanism of resistance
The majority of antiherpetic drugs in clinical use are nucleoside analogues. ACV is a guanosine analogue, as is penciclovir, whereas cidofovir is a phosphonate molecule derived from cytidine. Foscarnet presents a very different structure, analogous to a pyrophosphate.
ACV and penciclovir mechanism of action involves two viral enzymes: TK for the first phosphorylation of the activation step and DNA polymerase, which is the target of the triphosphate form. For cidofovir, only two phosphorylations
Management of acyclovir-resistant HSV infections
To manage ACV-resistant infections, several antiviral drugs may be used. Most of ACV-resistant HSV isolates are also resistant to penciclovir although rarely, some isolates resistant to ACV but susceptible to penciclovir have been reported; the mechanism of resistance to ACV of these strains was either an altered TK (Boyd et al., 1993) or a mutation in viral DNA polymerase (Chiou et al., 1995). Foscarnet and cidofovir act directly on viral DNA polymerase without previous activation by viral TK
In vitro detection of resistance
In vitro evaluation of HSV susceptibility to antiviral drugs is based on the determination of viral replication inhibition in the presence of increasing concentrations of antiviral drug. Three techniques are available to reveal viral replication: plaque reduction assay (PRA) which is the reference technique, DNA hybridization test (Swierkosz et al., 1987) and dye uptake method (Langlois et al., 1986). The two last techniques are less time consuming as the reading of cytopathic effect is
Thymidine kinase mutations associated with resistance
Our interest has first been focused on HSV TK, which is involved in 95% of ACV resistance cases. HSV TK is a 376 amino acid protein that is encoded by a gene of 1128 bp (UL 23; McKnight, 1980). It exhibits an ATP binding site (amino acid 51–63) and a nucleoside binding site (amino acid 168–176) as proposed by Darby et al. (1986). Six regions conserved among herpesviridae TK have also been located at amino acids 50–66, 79–91, 162–178, 212–226 and 281–292 (Balasubramaniam et al., 1990).
Fig. 2
DNA polymerase mutations associated with resistance
HSV DNA polymerase is a 1235 amino acid protein encoded by a 3705 bp gene (UL 30). It includes eight conserved regions in comparison with cellular or viral DNA polymerases; these regions are labeled I–VII according to their degree of conservation (region I being the most conserved), plus one region called A (Wong et al., 1988).
Mutations associated with resistance described in the literature are presented in the upper part of Fig. 3. These data are related to genetic characterization of about 15
Conclusion
The increasing use of ACV, especially in prophylaxis treatments among transplanted patients, has raised the fear of an increasing incidence of ACV-resistant infections. Recent survey studies have shown that this is not the case and that ACV resistance is mainly a concern for severely immunocompromised patients, such as those transplanted with bone marrow from allogeneic origin. When managing ACV-resistant infections, other antiviral drugs with different mechanisms of action may be used, such as
References (53)
- et al.
Acyclovir-resistant bilateral keratitis associated with mutations in the HSV-1 thymidine kinase gene
Exp. Eye Res.
(2000) - et al.
Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex virus
Virology
(1991) - et al.
A screening dye-uptake assay to evaluate in vitro susceptibility of herpes simplex virus to acyclovir
J. Virol. Meth.
(2002) - et al.
A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs
J. Biol. Stand.
(1986) - et al.
A point mutation in the thymidine kinase gene is responsible for acyclovir resistance in herpes simplex virus type 2 sequential isolates
Virus Res.
(1992) - et al.
Purification and photoaffinity labeling of herpes simplex virus type-1 thymidine kinase
J. Bio. Chem.
(1995) - et al.
Investigation of acyclovir-resistant herpes simplex virus I infection in a bone marrow transplantation unit: genotyping shows that different strains are involved
J. Hosp. Infect.
(2001) - et al.
Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene
J. Gen. Virol.
(2000) - et al.
Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary-structure predictions and conservation
J. Gen. Virol.
(1990) - et al.
Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues
J. Virol.
(2001)
Treatment of acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant
Bone Marrow Transplant
Antiviral susceptibilities of herpes simplex virus from immuncompetent subjects with recurrent herpes labialis: a UK-based survey
J. Antimicrob. Chemother.
Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern
Antiviral Chem. Chemother.
Analysis of nucleotide sequence variations in herpes simplex virus type 1 and 2, and varicella-zoster virus
Acta Virol.
Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene
Antiviral Chem. Chemother.
Survey of resistance of herpes simplex virus to acyclovir in northwest England
Antimicrob. Agents Chemother.
Thymidine-kinase negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate
Proc. Natl. Acad. Sci. USA
Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir
J. Antimicrob. Chem.
Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir
J. Gen. Virol.
Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir
New Engl. J. Med.
Evidence that the ‘active center’ of the Herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide
J. Gen. Virol.
Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8
Rev. Med. Virol.
The role of herpes simplex virus type 1 thymidine kinase in pathogenesis
J. Gen. Virol.
Acyclovir: discovery, mechanism of action and selectivity
J. Med. Virol.
Cited by (384)
Inhibition of herpes simplex virus by wedelolactone via targeting viral envelope and cellular TBK1/IRF3 and SOCS1/STAT3 pathways
2023, International Journal of Antimicrobial AgentsGenotypic testing improves detection of antiviral resistance in human herpes simplex virus
2023, Journal of Clinical VirologyAntiviral edible coatings and films: A strategy to ensure food safety
2023, Trends in Food Science and TechnologyBlue light irradiation exerts anti-viral and anti-inflammatory properties against herpes simplex virus type 1 infection
2023, Journal of Photochemistry and Photobiology B: BiologyHerpes simplex viruses
2023, Molecular Medical Microbiology, Third EditionAcyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives
2022, Biochemical Pharmacology